Undisclosed GPCR-targeted program(s)
Difficult-to-treat cancers
Phase 1Active
Key Facts
About Teon Therapeutics
Teon Therapeutics is a private, San Francisco-based biotech founded in 2019, operating at the intersection of cancer metabolism and immuno-oncology. The company is building a focused pipeline of first- and best-in-class oral GPCR-targeted therapies designed to reverse immune suppression in the tumor microenvironment. With a leadership team experienced in oncology drug development, Teon aims to expand the reach of immunotherapy beyond the current 12% of solid tumor patients who benefit, addressing a significant unmet need. The company is currently in the clinical stage, advancing its novel candidates.
View full company profileTherapeutic Areas
Other Difficult-to-treat cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Pipeline focused on CAR T-cell therapies | Mustang Bio | Clinical (exact phases not specified on provided pages) |